| 10.9174 0.247 (2.32%) | 12-01 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.65 | 1-year : | 15.94 |
| Resists | First : | 11.68 | Second : | 13.65 |
| Pivot price | 10.22 |
|||
| Supports | First : | 9.43 | Second : | 8.03 |
| MAs | MA(5) : | 10.67  |
MA(20) : | 10.04 |
| MA(100) : | 9.82 |
MA(250) : | 10.86 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 66.7 |
D(3) : | 61.5 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 15.48 | Low : | 5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PROF ] has closed below upper band by 27.6%. Bollinger Bands are 46% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.01 - 11.05 | 11.05 - 11.1 |
| Low: | 10.52 - 10.57 | 10.57 - 10.61 |
| Close: | 10.86 - 10.94 | 10.94 - 11.03 |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Mon, 13 Nov 2023
MOPH and partners mark World Diabetes Day| Gulf Times - Gulf Times
Wed, 08 Nov 2023
Profound Medical to Participate in the Stifel 2023 Healthcare ... - Yahoo Finance
Sun, 05 Nov 2023
Profound Medical Corp. (NASDAQ:PROF) Q3 2023 Earnings Call ... - Yahoo Finance
Tue, 10 Oct 2023
Profound Medical 2023 Virtual Analyst & Investor Day Agenda - Yahoo Finance
Mon, 25 Sep 2023
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA ... - Yahoo Finance
Tue, 19 Sep 2023
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference - Financial Post
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 21 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 40.9 (%) |
| Shares Short | 263 (K) |
| Shares Short P.Month | 248 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.79 |
| Profit Margin | 0 % |
| Operating Margin | -379.7 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -59.2 % |
| Qtrly Rev. Growth | -15.2 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -7.88 |
| PEG Ratio | 0 |
| Price to Book value | 6.07 |
| Price to Sales | 36.24 |
| Price to Cash Flow | -10.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|